Delivery Order SPE2DB20D2104-SPE2DB25FNBAG
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Letrozole 2.5 mg tablets (90-count units) on September 11, 2025, with a ceiling value of $1,448.81 and an ultimate completion date of September 12, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role as...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Letrozole 2.5 mg tablets in quantities of 30 units, with a ceiling value of $4,624.30. This is a firm fixed-price delivery order with an ultimate completion date of September 11, 2025, and represents a non-competitive set-aside contract. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Letrozole 2.5 mg tablets in quantities of 90 units, with a contract ceiling value of $2,110.12. This is a firm fixed price delivery order with an ultimate completion date of September 16, 2025, and was awarded without a set-aside designation through competitive procurement. The place of performance is located in Conshohocken, Pennsylvania, which serves as...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Letrozole 2.5 mg tablets in quantities of 90 units at a firm fixed price of $1,271.50. This is a non-set-aside competitively awarded contract with an ultimate completion date of August 14, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a single transaction within AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Letrozole 2.5 mg tablets in quantities of 90 units, with a contract ceiling value of $2,163.36. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 14, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract contains no set-aside designation, indicating the award was made...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Letrozole 2.5 mg tablets (30-count units) with a ceiling value of $1,444.11. The contract is structured as a firm fixed price delivery order with an ultimate completion date of September 3, 2025, and was awarded on a competitive basis without set-aside designation. AmerisourceBergen's corporate office, located in Conshohocken, Pennsylvania—which serves as both the vendor's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Letrozole 2.5 mg tablets in quantities of 90 units, valued at $1,403.88. This firm fixed price delivery order, which is not set-aside and was competitively awarded, is set for ultimate completion on July 29, 2025. The contract represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the federal government, with performance occurring at the...
- The Defense Logistics Agency (DLA) awarded a $1,145.15 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Letrozole 2.5 mg tablets in quantities of 30. The contract, which is a firm fixed price delivery order with no set-aside designation, is scheduled for completion by July 28, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award represents a competitive procurement action and reflects AmerisourceBergen's role as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Letrozole 2.5 mg tablets in quantities of 90 tablets at a ceiling value of $5,500.60. This delivery order is structured as a firm fixed price contract with no set-aside designation, indicating it was competitively awarded. The ultimate completion date is set for April 25, 2025, and the place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Letrozole 2.5 mg tablets in quantities of 90 units. This contract, valued at $1,802.80 with a firm fixed price structure, represents a non-set-aside, competitively awarded procurement supporting federal medical supply needs. The order is scheduled for completion by July 29, 2025, and will be fulfilled from the contractor's corporate office location in Conshohocken,...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FNBAGDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Letrozole 2.5 mg tablets in quantities of 30 units, with a ceiling value of $3,570.36. This is a firm fixed price delivery order with an ultimate completion date of September 22, 2025, and was awarded without a set-aside designation through open competition. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a task order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million and extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. Letrozole, an aromatase inhibitor used in breast cancer treatment, falls within the company's extensive portfolio of specialty medications and brand-name drugs delivered through this contract vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.6k | 9/19/25 |